Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Amprolium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.85 |
| ▸ | SLC19A2 | O60779 | 1/20 | 0.85 |
| ▸ | USP2 | O75604 | 1/20 | 0.85 |
| ▸ | LMNA | P02545 | 1/20 | 0.85 |
| ▸ | CASP1 | P29466 | 1/20 | 0.85 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.85 |
| ▸ | TKT | P29401 | 4/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.30 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amprolium Ion SCHEMBL29910331 | 0.93 | KDM4E (0.98) | KDM4ESLC19A2USP2LMNACASP1 | |
| Amprolium Ion SCHEMBL362893 | 0.93 | KDM4E (0.98) | KDM4ESLC19A2USP2LMNACASP1 | |
| Amprolium Ion SCHEMBL28047744 | 0.93 | KDM4E (0.98) | KDM4ESLC19A2USP2LMNACASP1 | |
| Amprolium Ion SCHEMBL29737311 | 0.92 | KDM4E (1.00) | KDM4ESLC19A2USP2LMNACASP1 | |
| Amprolium Ion SCHEMBL204023 | 0.92 | KDM4E (1.00) | KDM4ESLC19A2USP2LMNACASP1 | |
| Amprolium Ion SCHEMBL363586 | 0.92 | KDM4E (0.95) | KDM4ESLC19A2USP2LMNACASP1 | |
| Amprolium Ion SCHEMBL29387363 | 0.92 | KDM4E (0.95) | KDM4ESLC19A2USP2LMNACASP1 | |
| Amprolium Ion SCHEMBL204024 | 0.91 | KDM4E (0.98) | KDM4ESLC19A2USP2LMNACASP1 | |
| Amprolium Ion SCHEMBL20659804 | 0.91 | KDM4E (0.98) | KDM4ESLC19A2USP2LMNACASP1 | |
| Amprolium Ion SCHEMBL7107461 | 0.84 | KDM4E (0.83) | KDM4ESLC19A2USP2LMNACASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102105438-B | Process for the synthesis of substituted 4-amino-pyrimidines | DSM IP ASSETS BV | 2014-07-16 | — | — | CN | disclosed |
| EP-2307355-B1 | Novel synthesis of substituted 4-amino-pyrimidines | DSM IP ASSETS BV (NL) | 2013-11-06 | — | — | EP | disclosed |
| US-8252927-B2 | Synthesis of substituted 4-amino-pyrimidines | DSM IP ASSETS B.V. (NL) | 2012-08-28 | — | — | US | disclosed |
| US-20110178300-A1 | NOVEL SYNTHESIS OF SUBSTITUTED 4-AMINO-PYRIMIDINES | DSM IP ASSETS B.V. (NL) | 2011-07-21 | — | — | US | disclosed |
| CN-102105438-A | Novel synthesis method of substituted 4-amino-pyrimidine compounds | DSM IP ASSETS BV | 2011-06-22 | — | — | CN | disclosed |
| EP-2307355-A1 | Novel synthesis of substituted 4-amino-pyrimidines | DSM IP Assets B.V. (NL) | 2011-04-13 | — | — | EP | disclosed |
| WO-2010010113-A1 | Novel synthesis of substituted 4-amino-pyrimidines | DSM IP ASSETS B.V. (NL) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178300-A1 | NOVEL SYNTHESIS OF SUBSTITUTED 4-AMINO-PYRIMIDINES | IL4I1, CCNB1, VKORC1 | KDM4E 951/4885SLC19A2 9/4885USP2 4351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.